The bill CS/CS/HB 1617 introduces new regulations for stem cell therapy in Florida, permitting allopathic and osteopathic physicians to perform non-FDA approved therapies under specific conditions. It emphasizes ethical sourcing of stem cells, explicitly prohibiting the use of those derived from aborted fetuses, while promoting the use of adult stem cells and umbilical cord blood. The legislation sets forth stringent requirements for the facilities from which stem cells are obtained, mandating compliance with current good manufacturing practices and ensuring that stem cells are certified and viable for use.

Furthermore, the bill requires physicians to provide clear notices in advertisements regarding the unapproved status of the therapies and to obtain informed consent from patients prior to treatment. The consent form must detail the treatment's nature, associated risks, and encourage patients to consult with their primary care providers. The bill also outlines disciplinary actions for physicians who violate these provisions and empowers medical boards to adopt necessary implementation rules. The act is scheduled to take effect on July 1, 2025.